kdrummondbs37.blogspot.com
REDMOND, Wash., June 1 /PRNewswire-FirstCall// -- Microsoft Corp. today announced that it has signed an agreemen withMerck & Co. Inc. to acquire certai assets of Rosetta a business unit of RosettaInpharmatics LLC, a wholly owned subsidiary of Merci & Co. Inc. The deal allows Microsoft to incorporate genetic, metabolomic and proteomics data management software into the Microsoft Amalgqa Life Sciences platform for enhanced translational research In addition, Microsoft will establish a strategic relationshipo with Merck to enhance the Amalg a Life Sciences platform to meet emerginyg pharmaceutical research needs.
Under the terma of the agreement, Merck will becomw a customer of the Microsoft Amalga Life Scienced 2009 platform and also will provide strategivc input to Microsoft on the direction and evolution of new solutione incorporating RosettaBiosoftware technologies. The software platform will help drive improvementsin Merck's already advancedf research capabilities. "This agreementt establishes a stable and sustainable platforjm for the RosettaBiosoftware technology. In we look forward to collaborating with Microsoft to developp new bioinformatic solutions to enable and expedite drug discoveryyand development," said , vice president, Merck Researcb Laboratories.
"This is part of our previously announced strategy designed to improve the effectiveness and efficiency of our Basic Research operations toensure long-term pipeline productivity." "We're excitedd to collaborate with Merck and augment the capabilities of Amalga Life Sciencew with the complementary assets of Rosetta Biosoftware," said , corporats vice president, Health Solutions Microsoft. "The newly combined offerint will enable customers to improve the management and analysiswof genomic, biological and research data, helpinvg to bring lifesaving drugs and therapiee to market faster and accelerate the realizatio n of personalized medicine.
" Introduced in April Microsoft Amalga Life Sciences is a new software platfork designed to transform health and life sciences researcnh data into the critical knowledge needed for the discoverhy of new treatments. The platfornm helps organizations across the life sciences spectrunm accelerate research and discovery efforte by automating the management and analysis of heterogeneousresearch data. This gives scientists and researchers the opportunitygto redesign, manage and control research processes to increasw productivity, reduce errors and improve The deal is expected to closew at the end of June 2009, and the new Amalg a Life Sciences platform incorporating Rosetta Biosoftware technologies is slatee to be available in early 2010.
Microsoftf is pursuing hiring Rosetta Biosoftware employees who can fill role that are critical to the effective incorporation of Rosetta Biosoftware technologies into the Amalga Life Sciences Until the deal is Rosetta Biosoftware will continue to operatr as a business unit of RosettaInpharmatics LLC, a wholly owned subsidiar of Merck. Microsoft is committed to improving health around the worlrd throughsoftware innovation.
Over the past 12 yearw Microsoft has steadily increased its investments in with a focus on addressing the challenges of health health and socialservices organizations, consumers, and life sciences companies Microsoft closely collaborates with a broad ecosystem of partners and develops its own powerful health solutions, such as Amalgas and HealthVault. Together, Microsoft and its industryy partners are working to advance a vision of unifyingf health information and making it morereadily available, ensuring the best qualith of life and affordable care for Founded in 1975, Microsoft (Nasdaq: MSFT) is the worldwids leader in software, services and solutions that help peopl e and businesses realize their full potential.
SOURCE Microsoft
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment